Previous 10 | Next 10 |
Longboard Pharmaceuticals, Inc. (Nasdaq: LBPH), a clinical-stage biopharmaceutical company focused on developing novel, transformative medicines for neurological diseases, today announced that Brandi Roberts, Longboard’s Chief Financial Officer, will present at the 22nd Annual Needham Vi...
SAN DIEGO and GAINESVILLE, Ga., April 05, 2023 (GLOBE NEWSWIRE) -- Societal CDMO, Inc. (“Societal CDMO”; NASD: SCTL ), a contract development and manufacturing organization (CDMO), today announced that it has been selected by Longboard Pharmaceuticals, Inc. (NASD: ...
2023-03-28 17:27:17 ET Gainers: Arcturus Therapeutics ( ARCT ) +15% . lululemon athletica ( LULU ) +11% . Fate Therapeutics ( FATE ) +5% . Kezar Life Sciences ( KZR ) +5% . Longboard Pharmaceuticals ( LBPH ) +4% . Losers: ...
Longboard Pharmaceuticals, Inc. (LBPH) Q4 2022 Results Earnings Conference Call March 2, 2023, 04:30 PM ET Company Participants Brandi Roberts - Executive Vice President and Chief Financial Officer Kevin Lind - President and Chief Executive Officer Randall Kaye - Execu...
Longboard Pharmaceuticals press release ( NASDAQ: LBPH ): FY GAAP EPS of -$2.56 beats by $0.03 . Co currently estimates 2023 operating expenses in the $57.0 to $63.0 million range. For further details see: Longboard Pharmaceuticals reports FY 2022 results
LP352 Phase 1b/2a PACIFIC Study remains on track to complete enrollment in the first half of 2023, with topline data expected in the second half of 2023 LP659 Phase 1 initiation of first in-human clinical study on track for first half of 2023, with Phase 1 topline single-ascending dose (S...
Longboard Pharmaceuticals, Inc. (Nasdaq: LBPH), a clinical-stage biopharmaceutical company focused on developing novel, transformative medicines for neurological diseases, today announced that it plans to release 2022 financial results and provide a corporate update on March 2, 2023. The Compan...
Longboard Pharmaceuticals, Inc. (Nasdaq: LBPH), a clinical-stage biopharmaceutical company focused on developing novel, transformative medicines for neurological diseases, today announced the closing of its previously announced underwritten public offering of 5,750,000 shares of its voting common...
Longboard Pharmaceuticals ( NASDAQ: LBPH ) announced underwritten public offering of 5M shares at a price to the public of $4.00 per share. The gross proceeds are expected to be $20M. Underwriters' have a 30-day option to purchase up to an additional 750,000 shares. The of...
Longboard Pharmaceuticals, Inc. (Nasdaq: LBPH), a clinical-stage biopharmaceutical company focused on developing novel, transformative medicines for neurological diseases, today announced the pricing of its previously announced underwritten public offering of 5,000,000 shares of its voting common...
News, Short Squeeze, Breakout and More Instantly...
Longboard Pharmaceuticals Inc. Company Name:
LBPH Stock Symbol:
NASDAQ Market:
Longboard Pharmaceuticals Inc. Website:
2024-07-16 13:46:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...
2024-07-06 15:36:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...
2024-07-02 10:45:05 ET Ford Motor Co. (F) F is trading UP for the last 5 days, and it at trading at $12.82 with volume of 15,047,573 and a one day change of $0.06 (0.47%). Ford Motor Co. has a 52-week low of 9.63 and a 52-week high of $15.42. The business's 50-day moving average pri...